Trexquant Investment LP Makes New Investment in Sarepta Therapeutics, Inc. $SRPT

Key Points

• Trexquant Investment LP has made a new investment of approximately $12 million in Sarepta Therapeutics by acquiring 187,984 shares, which represents about 0.19% of the company's stock.
• Sarepta Therapeutics' stock received mixed reviews from analysts, with BMO Capital Markets raising its price target to $50, while TD Cowen set a lower price target of $24, reflecting varying perspectives on its market performance.
• The company reported a quarterly revenue of $611.09 million, significantly above analysts' expectations, showcasing a year-over-year growth of 68.4%.

Trexquant Investment LP purchased a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 187,984 shares of the biotechnology company's stock, valued at approximately $11,997,000. Trexquant Investment LP owned 0.19% of Sarepta Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in SRPT. FORA Capital LLC purchased a new position in Sarepta Therapeutics during the first quarter valued at $386,000. University of Wisconsin Foundation purchased a new position in shares of Sarepta Therapeutics during the 1st quarter worth $1,769,000. Jump Financial LLC boosted its holdings in Sarepta Therapeutics by 218.2% in the 1st quarter. Jump Financial LLC now owns 5,785 shares of the biotechnology company's stock valued at $369,000 after purchasing an additional 3,967 shares during the last quarter. AlphaQuest LLC acquired a new position in Sarepta Therapeutics in the first quarter valued at approximately $141,000. Finally, T. Rowe Price Investment Management Inc. grew its holdings in shares of Sarepta Therapeutics by 2.1% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 1,997,991 shares of the biotechnology company's stock worth $127,512,000 after purchasing an additional 41,408 shares during the period. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Trading Up 2.1%

Shares of NASDAQ:SRPT traded up $0.37 during midday trading on Wednesday, reaching $18.53. The company's stock had a trading volume of 2,194,600 shares, compared to its average volume of 6,349,093. Sarepta Therapeutics, Inc. has a 1 year low of $10.41 and a 1 year high of $138.81. The business has a 50 day moving average price of $17.69 and a 200 day moving average price of $45.76. The company has a quick ratio of 1.81, a current ratio of 2.89 and a debt-to-equity ratio of 0.84. The firm has a market cap of $1.81 billion, a price-to-earnings ratio of -21.30 and a beta of 0.49.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $1.13. The business had revenue of $611.09 million for the quarter, compared to analysts' expectations of $530.66 million. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The company's quarterly revenue was up 68.4% on a year-over-year basis. During the same period last year, the company earned $0.07 earnings per share. Research analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on SRPT. Mizuho reissued a "neutral" rating and issued a $14.00 target price (down previously from $40.00) on shares of Sarepta Therapeutics in a research report on Monday, July 21st. William Blair reissued an "outperform" rating on shares of Sarepta Therapeutics in a research report on Tuesday, July 29th. Jefferies Financial Group decreased their target price on Sarepta Therapeutics from $40.00 to $35.00 and set a "buy" rating for the company in a research note on Thursday, July 24th. UBS Group reaffirmed a "neutral" rating on shares of Sarepta Therapeutics in a report on Monday, July 21st. Finally, Bank of America increased their price target on shares of Sarepta Therapeutics to $17.00 and gave the stock an "underperform" rating in a research note on Wednesday, August 20th. Eight investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and six have issued a Sell rating to the company. According to data from MarketBeat.com, Sarepta Therapeutics has a consensus rating of "Hold" and a consensus price target of $43.50.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.